MedTrace Logo

VEGF Imaging in Renal Cell Carcinoma

NCT00831857 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2024-05-06

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC. 89Zr-bevacizumab PET imaging will be regarded a promising biomarker if the target for treatment (VEGF) can be visualised and if uptake changes after institution of treatment.

Conditions

Interventions

OTHER

89Zr-Bevacizumab PET-scan

At baseline, after two weeks of treatment and after 6 weeks of treatment.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Sjoukje F. Oosting, MD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831857 on ClinicalTrials.gov